Evidence map›Paper›PMID 38320232›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Reply to A.W. Chan et al.

Erin F Gillespie, Max Vaynrub, Jonathan T Yang

Abstract readLetterComment
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Erin F GillespieErin F. Gillespie, MD, MPH, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Max Vaynrub, MD, Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY; and Jonathan T. Yang, MD, PhD, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1386-1542
Max VaynrubErin F. Gillespie, MD, MPH, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Max Vaynrub, MD, Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY; and Jonathan T. Yang, MD, PhD, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7364-3259
Jonathan T YangErin F. Gillespie, MD, MPH, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Max Vaynrub, MD, Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY; and Jonathan T. Yang, MD, PhD, Department of Radiation Oncology, University of Washington, Seattle, WA, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancerK08CA252640 · NCI · UNIVERSITY OF WASHINGTON · PI GILLESPIE, ERIN FAYE · 2020 to 2025
$1.3M
NCI NIH HHS K08 CA252640
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38320232
PMCPMC11095854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.